Comparative Efficacy of Etmaben and Empagliflozin in Mono- and Combined Therapy of Experimental Chronic Heart Failure
https://doi.org/10.33647/2713-0428-20-3E-187-190
Abstract
The cardiotropic activity of etmaben, a malonic acid derivative, has been confirmed by a number of studies. The possibility of using empagliflozin in chronic heart failure has been proven in a number of preclinical and clinical studies. In this study, the efficacy of the drugs in monotherapy and combined use regimens is compared using a model of experimental chronic heart failure in rats. The most effective treatment regimen was found to be etmaben; its combination with empagliflozin led to a decrease in effectiveness, regardless of which of these drugs was the starting drug.
About the Authors
D. Yu. Ivkin
Saint Petersburg State Chemical and Pharmaceutical University of the Ministry of Health Care of Russia
Russian Federation
Russian Federation
Dmitry Yu. Ivkin, Cand. Sci. (Biol.), Assoc. Prof.
197376, Sant Petersburg, Professora Popova Str., 14, lit. A
M. V. Krasnova
Saint Petersburg State Chemical and Pharmaceutical University of the Ministry of Health Care of Russia
Russian Federation
Russian Federation
Marina V. Krasnova
197376, Sant Petersburg, Professora Popova Str., 14, lit. A
E. D. Semivelichenko
Saint Petersburg State Chemical and Pharmaceutical University of the Ministry of Health Care of Russia
Russian Federation
Russian Federation
Evgeniy D. Semivelichenko
197376, Sant Petersburg, Professora Popova Str., 14, lit. A
A. A. Karpov
Saint Petersburg State Chemical and Pharmaceutical University of the Ministry of Health Care of Russia
Russian Federation
Russian Federation
Andrew A. Karpov, Cand. Sci. (Med.)
197376, Sant Petersburg, Professora Popova Str., 14, lit. A
V. E. Kovanskov
Saint Petersburg State Chemical and Pharmaceutical University of the Ministry of Health Care of Russia
Russian Federation
Russian Federation
Vladislav E. Kovanskov
197376, Sant Petersburg, Professora Popova Str., 14, lit. A
S. V. Okovitiy
Saint Petersburg State Chemical and Pharmaceutical University of the Ministry of Health Care of Russia
Russian Federation
Russian Federation
Sergey V. Okovitiy, Dr. Sci. (Med.), Prof.
197376, Sant Petersburg, Professora Popova Str., 14, lit. A
References
1. Ivkin D.Yu., Karpov A.A. Eksperimental'naya otsenka effektivnosti i bezopasnosti novogo proizvodnogo propandiovoy kisloty s kardiotropnym deystviem Experimental evaluation of the effectiveness and safety of a new propandic acid derivative exhibiting cardiotropic action]. Biomeditsina [Journal Biomed]. 2022;18(3):109–112. (In Russian). DOI: 10.33647/2074-5982-18-3-109-112
2. Ivkin D.Yu., Karpov A.A., Dracheva A.V., Pitukhina N.N., Ivkina A.S., Buryakina A.V., Teslev A.A. Vliyanie proizvodnogo benzoynoy kisloty na formirovanie eksperimental'noy khronicheskoy serdechnoy nedostatochnosti [The influence of a benzoic acid derivative on the formation of experimental chronic heart failure]. Farmatsiya [Pharmacy]. 2016;63(4):49–52. (In Russian).
3. Ivkin D.Yu., Krasnova M.V., Okovity S.V., Karpov A.A., Kulikov A.N., Yeletskaya E.I. Ob effektivnosti empagliflozina v terapii eksperimental'nogo infarkta miokarda [Efficacy of empagliflozin in the treatment of experimental myocardial infarction]. Razrabotka i registratsiya lekarstvennykh sredstv [Drug development & registration]. 2023;12(4):136–145. (InRussian). DOI: 10.33380/2305-2066-2023-12-4-1588
4. Karpov A.A., Ivkin D.Yu., Dracheva A.V., Pitukhina N.N., Uspenskaya Yu.K., Vaulina D.D., Uskov I.S., Eyvazova Sh.D., Minasyan S.M., Vlasov T.D., Buryakina A.V., Galagudza M.M. Modelirovanie postinfarktnoy serdechnoy nedostatochnosti putem okklyuzii levoy koronarnoy arterii u krys: tekhnika i metody morfofunktsional'noy otsenki [Rat model of post-infarct heart failure by left coronary artery occlusion: Technical aspects, functional and morphological assessment]. Biomeditsina [Journal Biomed]. 2014;3:32–48. (In Russian).
5. Krasnova M., Kulikov A., Okovityi S., Ivkin D., Karpov A., Kaschina E., Smirnov A. Comparative efficacy of empagliflozin and drugs of baseline therapy in post-infarct heart failure in normoglycemic rats. Naunyn-Schmiedeberg’s Arch. Pharmacol. 2020;393(9):1649–1658. DOI: 10.1007/s00210-020-01873-7
Review
For citations:
Ivkin D.Yu., Krasnova M.V., Semivelichenko E.D., Karpov A.A., Kovanskov V.E., Okovitiy S.V. Comparative Efficacy of Etmaben and Empagliflozin in Mono- and Combined Therapy of Experimental Chronic Heart Failure. Journal Biomed. 2024;20(3E):187-190. (In Russ.) https://doi.org/10.33647/2713-0428-20-3E-187-190
Views:
106
Email this article 
